RecruitingNot applicableNCT05098665

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

Studying Wild type ATTR amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Richmond Research Institute
Principal Investigator
Tamer Rezk, MBBS MRCP PhD
National Amyloidosis Centre, Royal Free Hospital
Intervention
Telemonitoring service(combination_product)
Enrollment
320 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (1)

Collaborators

Richmond Pharmacology Limited · National Amyloidosis Centre

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05098665 on ClinicalTrials.gov

Other trials for Wild type ATTR amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Wild type ATTR amyloidosis

← Back to all trials